UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
[X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q
For Period Ended: December 31, 2001 SEC FILE NUMBER 000-26927
CUSIP NUMBER 66986S 10 7
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR For Period Ended: December 31, 2000
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates: Entire Form 10-K
Part I - Registrant Information
Full Name of Registrant Novamed, Inc.
----------------
Former Name if Applicable N/A
-----------
Address of Principal Executive Office:
623 Hoover St., N.E.
Minneapolis, MN
Part II--RULES 12b-25 (b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b) the following
should be completed. (Check box if appropriate)
[X] (a) The reasons described in reasonable detail in Part III of
this form could not be eliminated without unreasonable effort or
expense;
[X] (b) The subject annual report, semi-annual report, transition
report on Form 10-K, Form 2-F, 11- F, or From N-SAR, or portion
thereof will be filed on or before the fifteenth calendar day
following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q, or portion thereof will
be filed on or before the fifth calendar day following the
prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
Part III - Narrative
State below in reasonable detail the reasons why form 10-K, 11-K, 20-F,
10-Q or N-SAR or portion thereof could not be filed within the prescribed time
period.
The Company entered into an agreement to settle debt represented by
outstanding debentures in late December, 2001. The actual finalization of the
settlements did not occur until March of 2002, which created problems for the
auditors in finishing the financial statements. As a result of the late
settlement of these accounts, the Company's management was unable to compile the
information that is required to be disclosed in its 10-K in a timely manner.
Consequently, the Company will not be able to file its Form 10-K on time without
unreasonable effort or expense.
Part IV - Other Information
(1) Name and telephone number of person to contact in regard to this
notification.
Ruairidh Campbell President (612) 378-1437
---------------------------------------------------------
(Name) (Title) (Telephone Number)
(2) Have all other periodic reports required under section 13 or
15(d) of the Securities Exchange Act of 1934 or section 30 of the
Investment Company Act of 1940 during the 12 months or for such
shorter period that the registrant was required to file such
report(s) been filed? If the answer if no, identify report(s).
(X) Yes ( ) No
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year
will be reflected by the earnings statements to be included in
the subject report or portion thereof?
( ) Yes (X ) No
If so, attach an explanation of the anticipated change, both
narrative and quantitatively, and, if appropriate, state the
reasons why a reasonable estimate of the results cannot be made.
N/A
Novamed, Inc.
--------------------------------------------------------------------------------
(Name of Registrant as specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: April 1, 2002 By: /s/ Ruairidh Campbell
------------- --------------------------
Name: Ruairidh Campbell
Title: President